clinical outcomes amongst the subgroups. Two years data of the full cohort will be available upon presentation. Conclusions: The Energy demonstrates very good results which were promising for subgroups with diabetes, small vessels and even acute coronary syndrome. Utility of such modern bare metal stent platforms is still relevant in the era of drug-eluting stents.
Background: Late target lesion revascularization (TLR) and stent thrombosis with drug-eluting stents (DES) remain a concern, especially in the thrombogenic milieu of acute coronary syndrome (ACS). This study aims to investigate the long-term safety and efficacy of everolimus-(EES) and zotarolimus-eluting stents (ZES) to 1st-generation sirolimus-eluting stents (SES) and bare metal stents (BMS) in ACS patients. Methods: We identified 1612 patients presenting with ACS who received either BMS, SES, ZES or EES. The primary end points were probable or definite stent thrombosis (ST) and major adverse cardiovascular event (MACE) defined as composite of allcause death, myocardial infarction, or TLR up to 3 years. Results: The 3-year MACE was 44.9% in the BMS group versus 34.6% in the SES group versus 21.8% in the ZES group and 18.5% in the EES group (p <0.001). Mortality at 3 years was highest in the BMS group (36.7%) than in the SES, ZES or EES groups (22.5% vs 12.9% vs 12%, respectively; p <0.001). The 30-day ST was highest in the SES group (5.1%) compared to BMS group (1.4%), ZES group (2.3%) and EES group (1.1%) (p <0.001).These findings were reflected at 3 years (7.5% vs 1.9% vs 2.3% vs 1.5%, respectively; p <0.001). Conclusions: The newer drug-eluting stents, EES and ZES, have shown improved rate of MACE over BMS and 1st-generation SES. In addition, ST rates up to 3 years in EES and ZES were comparable to BMS in ACS patients.
TCT-186
Comparison of 5-year outcomes between drug-eluting and bare-metal stents in patients after acute myocardial infarction with or without diabetes Background: Patients with acute myocardial infarction (AMI) have had conflicting results between drug-eluting stents (DES) and bare-metal stents (BMS). The aim of this study was to compare 5-year outcomes between DES and BMS in Asian patients after AMI with or without diabetes (DM). Methods: This study enrolled 1137 consecutive AMI patients who received stent implantation in a single tertiary medical center from 2004 to 2011. The patients were divided into DES (N¼210, 60 DM patients) and BMS group (N¼927, 302 DM patients)in the study. The 5-year outcomes were collected, including early thrombosis events (< 1 month), late thrombosis events (1-12 months), very late thrombosis events (>12 months), time to the occurrence of myocardial re-infarction and time to cardiovascular death. Results: The baseline characteristics and complication rates were not different between BMS and DES study groups. BMS and DES had almost identical rate of early thrombosis (0.9% vs 0%, p¼0.117), late thrombosis (2.2% vs 1.0%, p¼0.252) and very late thrombosis (0.8% vs 0%, p¼0.207). The Kaplan-Meier analysis showed there was no difference of 5-year myocardial re-infarction event rate and 5-year cardiovascular survival between DES and BMS groups, whether DM or non-DM patients (Please see Figure) . TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM Background: Polytetrafluoroethylene (PTFE)-covered stents have improved the inhospital clinical outcomes of patients with coronary perforation. However, there are a few reports regarding their long-term outcomes. Methods: We analyzed data that was prospectively collected from 17277 patients who underwent percutaneous coronary intervention in New Tokyo Hospital between January 2004 and December 2012. Of the total, we identified 238 (1.38%) patients with coronary perforation. We then evaluated their mid-term clinical outcomes. The study endpoints were major adverse cardiac events (MACEs), defined as cardiac death, myocardial infarction (MI), and target lesion revascularization (TLR). Furthermore, individual parameters, including all-cause death, cardiac death, MI, TLR and stent thrombosis (ST) during the follow-up period, were evaluated. Results: Among the 238 patients with coronary perforation, 42 (17.6%) were treated with PTFE-covered stents. All patients were followed-up for over 6 months (median follow-up period, 1015 days; interquartile range, 401-1739 days). Although the allcause death rate was relatively high, at 11.9% because of complications associated with coronary perforation, the cardiac death rate was 2.6% at 1 year (Figure) . TLR occurred in 5 patients, and it occurred within 3 months in 3 of these patients. MI occurred in 1 patient because of side branch occlusion following PTFE-covered stent implantation. No definite or probable ST was found.
Conclusions:
The 1-year cardiac death rate of 2.6% in this study indicates a better mid-term clinical outcome of PTFE-covered stenting for coronary perforation. Background: The aim of this study was to investigate safety and efficacy of secondgeneration zotarolimus-eluting Resolute stents and everolimus-eluting Xience V stents in bifurcation lesions. Methods: In TWENTE -a prospective, randomized DES trial -PCI patients were randomized for treatment with contemporary Resolute or Xience V stents. Clinical endpoints were adjudicated by an external independent clinical events committee (Cardialysis CRO, Rotterdam, The Netherlands). Target vessel failure (TVF; cardiac death, target vessel-related myocardial infarction, and clinically-indicated target vessel revascularization), the primary endpoint of the TWENTE trial, was assessed after 2 years. Results: Among the 1,391 patients of the TWENTE trial, 362 (26%) patients were treated for at least one bifurcation lesion. Of these patients, 179 and 183 were randomized for treatment with Resolute and Xience V stents, respectively. At 2-year follow-up, TVF (12.8% vs. 11.5%; p¼0.69) and a patient-oriented composite endpoint (17.3% vs. 16.9%; p¼0.92) did not differ significantly between stent arms. In addition, rates of definite and or probable stent thrombosis were low and similar for both stent arms (0.6% vs. 0.5%; p¼0.99). Within 213 (15.3%) patients, who were treated for bifurcation lesions with an additional treatment of the side-branch, there was also no significant difference in TVF between patients treated with Resolute (n¼98) and Xience V (n¼115) (8.2% vs. 11.3%; p¼0.44). Conclusions: Treatment of bifurcation lesions with Resolute and Xience V stents resulted in favorable and similar outcomes after 2 years in the randomized TWENTE trial. www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM-5:30 PM 
